Business
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025.
Jonathan Ernst | Reuters
President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments.
The agreements will cut prices of so-called GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026 and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January called TrumpRx.gov.
That means Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. Certain Medicare patients will pay a copay of $50 per month for all approved uses of injectable and oral GLP-1 drugs, including diabetes and obesity treatment.
Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month for everyone getting them through Medicare, Medicaid or TrumpRx, a senior administration official who declined to be named told reporters during a briefing Thursday.
Novo Nordisk’s oral version of its obesity injection Wegovy could enter the market by year-end, while Eli Lilly’s pill orforglipron could launch next year. The Food and Drug Administration on Thursday said it has awarded priority review vouchers, which expedite the review timelines of Eli Lilly’s pill.
Starting doses of existing injections like Novo’s Wegovy and Lilly’s Zepbound will be $350 per month on TrumpRX, but will “trend down” to $245 per month over a two-year period, another senior administration official said during the briefing.
Charts showing drug prices and information are displayed as U.S. President Donald Trump delivers remarks on lowering drug prices in the Oval Office at the White House on Nov. 6, 2025 in Washington, DC.
Andrew Harnik | Getty Images
Wegovy and Zepbound have not been covered by Medicare for weight loss, “and they’ve only rarely been covered by Medicaid,” Trump said in the Oval Office. “They’ve often cost consumers more than $1,000 per month, some a lot more than that. … That ends starting today.”
The deals are among the most politically significant announcements to date in the Trump administration’s push to rein in high U.S. drug costs by tying them to the lowest prices abroad. As part of the president’s “most favored nation” policy, he has announced deals with Pfizer, AstraZeneca and EMD Serono to sell certain drugs directly to patients at a discount, in exchange for exemptions from planned pharmaceutical tariffs.
“This is the biggest drug in our country, and that’s why this is the most important of all the [most favored nation] announcements we’ve made,” Health and Human Services Secretary Robert F. Kennedy Jr. said during the briefing. “This is going to have the biggest impact on the American people. All Americans, even those who are not on Medicaid, Medicare, are going to be able to get the same price for their drugs, for their GLP-1s.”
Kennedy claimed the American public will lose 125 million pounds by this time next year, saying the expanded access will have “dramatic effects on human health” in the U.S.
The event was delayed when a man who was standing behind Trump fainted.
President Donald Trump stands by as attendees help a man after he collapsed during during an event on lowering drug prices in the Oval Office at the White House on November 06, 2025 in Washington, DC.
Andrew Harnik | Getty Images
The list prices of existing obesity drugs – roughly $1,000 to $1,350 per month before insurance – are a huge barrier for patients, many of whom could benefit from their ability to promote weight loss and ease other related health complications such as cardiovascular risks and sleep apnea. Eli Lilly and Novo Nordisk already have programs to sell their weight loss drugs at a discount directly to cash-paying consumers, but the new agreements appear to take those efforts to boost access a step further.
Novo Nordisk and Eli Lilly have agreed to cut the price Medicare pays for GLP-1s it already covers for diabetes and other indications, along with those drugs for obesity, to $245 per month. The companies agreed to extend lower government pricing for their GLP-1 drugs – $245 per month across all other nonstarting doses – to all 50 Medicaid programs for all covered uses. States will have to opt into those prices, meaning some may not.
But Medicare coverage could have a bigger impact on who gets the drugs because the program covers about 66 million people, and is the primary source of insurance for people ages 65 and above. The new obesity drug coverage will be enabled through a pilot program designed to cover a majority of beneficiaries under Medicare Part D, which are the program’s prescription drug plans.
Another senior administration official said around 10% of Medicare beneficiaries will be eligible to receive GLP-1s for obesity and cardiovascular and metabolic benefits. Eligible patients will fall into three cohorts. The first includes those who are overweight, with a body mass index greater than 27 or with prediabetes or established cardiovascular disease.
The second group is people with obesity – with a BMI greater than 30 – and uncontrolled hypertension, kidney disease or heart failure. The third group is patients with severe obesity, or anyone with a BMI greater than 35.
GLP-1s for weight loss are approved for a much broader population: people who have obesity or are overweight with one related condition. The administration official said, “We are constraining the access for patients that will benefit clinically from it, we’ve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically.”
As part of the deals, Eli Lilly and Novo Nordisk also made similar pledges to the ones other drugmakers have made as part of Trump’s most favored nation agreements. The companies will guarantee most favored nation pricing on all new medicines they bring to market, provide that pricing to every state Medicaid program, offer at least U.S. net prices or most favored nation pricing on nearly all primary care drugs on TrumpRx and share savings from foreign drug price increases on existing products, one senior administration official said.
Also on Thursday, Eli Lilly said it would lower prices by $50 on its own direct-to-consumer platform, LillyDirect, which already offers Zepbound at a discount to cash-paying patients. The multidose pen of Zepbound will be available at $299 per month at the lowest dose, with additional doses being priced up to $449 per month.
Eli Lilly’s pill, once approved, will be available at the lowest dose starting at $149 per month.
A major pricing change
In a statement Thursday, Eli Lilly CEO David Ricks said the deal marks “a pivotal moment in U.S. health care policy and a defining milestone for Lilly,” which is focused on “improving outcomes, strengthening the U.S. healthcare system, and contributing to the health of our nation for generations to come.”
David Ricks, CEO of Eli Lilly, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
In a separate statement, Novo Nordisk CEO Mike Doustdar said, “today’s announcement will bring semaglutide medicines to more American patients at a lower cost.” Semaglutide is the active ingredient in Wegovy and Ozempic.
It’s not the first time the government has floated Medicare coverage of obesity drugs. Former President Joe Biden proposed a rule at the end of his term that would have allowed the program to cover those treatments, but the Trump administration in April declined to finalize the measure.
Biden’s proposal would have extended access to roughly 3.4 million Medicare beneficiaries. But it was controversial at the time, as it would cost taxpayers as much as $35 billion over nine years, a congressional analysis found.
But some health experts contend that covering the drugs could eliminate the downstream costs involved with treating obesity-related conditions.
Semaglutide is also included in the next round of Medicare drug price negotiations under the Inflation Reduction Act, which Biden signed into law in 2022. Trump is expected to unveil the new prices of the 15 drugs selected for those talks by Nov. 30.
Tirzepatide, the active ingredient in Eli Lilly’s Zepbound and diabetes injection Mounjaro, likely won’t be eligible for those negotiations until the end of the decade.
Business
Elon Musk just lost another lawsuit. Will he keep fighting?
Musk’s loss against OpenAI is the latest in a string of courtroom defeats.
Source link
Business
FTSE 100 up amid calmer bonds but oil rises again
The FTSE 100 closed higher on Monday, recouping most of Friday’s hefty falls amid a calmer bond market and as Iran responded to the latest US peace proposal.
The FTSE 100 closed up 128.38 points, 1.3%, at 10,323.75. The FTSE 250 ended up 15.56 points, 0.1%, at 22,611.70, but the AIM All-Share fell 8.72 points, 1.1%, at 800.17.
Iran said it had responded to a new US proposal aimed at ending the war, adding that diplomatic exchanges continue despite Iranian media reports describing Washington’s demands as excessive, AFP reported.
Washington and Tehran have been swapping proposals in an effort to end the conflict, which the US and Israel launched on February 28, but they have held only a single round of talks despite a fragile ceasefire.
“As we announced yesterday, our concerns were conveyed to the American side,” foreign ministry spokesman Esmaeil Baqaei told a news briefing, adding that exchanges were “continuing through the Pakistani mediator”.
Mr Baqaei defended Iran’s demands, including the release of Iranian assets frozen abroad and the lifting of long-standing sanctions.
“The points raised are Iranian demands that have been firmly defended by the Iranian negotiating team in every round of negotiations,” he said.
But with no signs of clear progress, the oil price remained inflated and volatile.
Brent crude for July delivery was trading at 110.80 dollars a barrel on Monday, up compared to 108.83 at the time of the equities close in London on Friday.
After a frantic Friday, the bond markets calmed, while sterling also rebounded as investors weighed the latest political developments.
The yield on UK 10-year gilts traded at 5.14% compared to 5.17% at the same time on Friday.
The pound traded at 1.3397 dollars on Monday afternoon, up from 1.3319 on Friday. Against the euro, sterling firmed to 1.1506 euros from 1.1462 on Friday.
Prime Minister Sir Keir Starmer insisted he would not set out a timetable to leave No 10 as potential leadership challenger Andy Burnham vowed to “change Labour” if he is successful in his effort to return to Parliament.
The Prime Minister said he still wants to lead Labour into the next general election amid calls from within the party to set out a timetable for his exit.
Greater Manchester Mayor Mr Burnham hopes to be Labour’s candidate in the Makerfield by-election, which could provide him with a route back to the Commons to challenge for the party leadership and the keys to Downing Street.
Speaking to broadcasters in London, Sir Keir said he was not going to set out a timetable to stand down if Mr Burnham returns to Westminster.
He added: “I do want to fight the next election. Obviously, I recognise that after the local election results, the elections in Wales and Scotland as well, that the first task is obviously turning things around and making sure that my focus is in the right place.”
Meanwhile, the International Monetary Fund said growth in the UK economy will be stronger this year than previously thought.
The IMF updated its growth projections a month after warning of a sharp slowdown caused by the global energy shock from the US-Iran war.
The influential financial body said it was now predicting UK gross domestic product to rise by 1% in 2026, higher than the 0.8% growth it was forecasting last month.
Responding to the latest report, Chancellor Rachel Reeves said: “The IMF upgrading its growth forecasts and backing our fiscal strategy is yet more proof that this Government has the right economic plan.”
In Europe, equity markets on Monday, the Cac 40 in Paris ended up 0.4%, and the Dax 40 in Frankfurt advanced 1.5%.
In New York, the Dow Jones Industrial Average was down 0.1%, the S&P 500 fell 0.4%, and the Nasdaq Composite was 0.7% lower.
On the FTSE 100, Whitbread closed up 2.3% after Corvex Management urged the Premier Inn owner to put itself up for sale, slamming its recently announced new five-year strategic plan.
In a damning letter to Whitbread management, the New York-based activist hedge fund called the status quo “untenable” and said that the need to pursue “meaningful strategic and structural reform had become unignorable”.
As a result, Corvex, which holds a stake of around 7% in Whitbread, said the only “credible” path to unlocking value at Whitbread is a sale of the company.
Anglo America fell 1.4% as it struck a deal to sell its portfolio of steelmaking coal mines in Australia to Dhilmar for up to 3.88 billion dollars in cash.
The London-based mining house said Dhilmar will pay the FTSE 100-listing 2.3 billion dollars upfront, and the deal has a price-linked earnout of up to 1.58 billion dollars.
Anglo American chief executive officer Duncan Wanblad said: “This agreement represents another major step in the simplification of our portfolio ahead of completing our merger with Teck. Through this transaction, we will complete our exit from steelmaking coal.”
Susannah Streeter, chief investment strategist at Wealth Club, said: “This not only strengthens the balance sheet, ahead of its planned merger with Canada’s Teck Resources, but also keeps it exposed to future strength in coal prices.”
Capita shares rose 8.9% as the London-based outsourcing and business services company said adjusted revenue rose 2.9% on-year in the first four months of 2026, which it said was in line with expectations.
Looking ahead, Capita said it continues to expect a low to mid-single digit revenue climb in Capita Public Service and expects mid-teen revenue growth in its Pension Solutions business.
The biggest risers on the FTSE 100 were Centrica, up 7.70p at 196.95p, National Grid, up 43.50p at 1,231.50p, Pearson, up 37.00p at 1,136.50p, Relx, up 81.00p at 2,504.00p, and SSE, up 74.00p at 2,345.00p.
The biggest fallers on the FTSE 100 were 3i Group, down 128.00p at 2,082.00p, Airtel Africa, down 15.60p at 312.80p, Mondi, down 16.40p at 734.60p, Polar Capital Technology Trust, down 12.50p at 659.00p and Diploma, down 95.00p at 6,625.00p.
Tuesday’s global economic calendar has UK consumer and wholesale inflation figures, eurozone inflation data and the minutes of the last Federal Open Market Committee meeting.
Tuesday’s local corporate calendar has full-year results from business services group DCC, half-year numbers from supplier of specialised technical products and services, Doploma, and electricals retailer Currys.
Business
Halifax could vanish from high streets after 173 years as Lloyds mulls major shake-up
Lloyds Banking Group is considering phasing out its Halifax brand, a move that could bring an end to the 173-year-old institution.
The Sun reports that bosses are expected to announce the end of Halifax as a standalone brand this summer.
It is understood that no definitive decisions have yet been made about the brand, which granted its first mortgage in 1853.
Should Halifax be phased out, account numbers would remain unchanged, and customers’ automatic protection under the Financial Services Compensation Scheme (FSCS) would be unaffected.
“We regularly look at the role our brands play in supporting our customers,” a spokesperson for Lloyds said.
“Our banking customers can already use any Lloyds, Halifax or Bank of Scotland branch, and see any of their products and services in any of their apps – there are no changes for our customers today.”
The Sun, citing industry insiders, reported that any transition would begin on 1 July when people will no longer be able to open new Halifax accounts online or through the app.
By October, Halifax will stop taking on new customers entirely and existing account holders will be gradually migrated to Lloyds Bank, the reports say.
Lloyds declined to comment on the potential timings for any plans.
Britain’s biggest mortgage lender made changes in 2025 that meant its three brands, Lloyds, Halifax and Bank of Scotland, could share branches and mobile banking services.
The shake-up meant some customers could access a branch that is closer to their home because they will be able to access face-to-face banking regardless of the brand.
However, the banking giant has also shut hundreds of high street branches over recent years.
It started another round of closures this month, which will see 95 branches shuttered across the three brands by March 2027.
The closures will leave the group with 610 branches in total, of which 306 are Lloyds, 238 Halifax and 66 Bank of Scotland.
Lloyds has said that all employees currently working at the affected branches will be offered alternative roles within the business or at other locations.
Halifax and Lloyds operate in the same market in England and Wales, while Bank of Scotland is the group’s only brand in the country.
-
Entertainment6 days agoConan O’Brien hat tricks as Oscar host
-
Tech1 week agoCould Contact-Tracing Apps Help With the Hantavirus? Not Really
-
Fashion5 days agoItaly’s Zegna Group’s Q1 growth boosted by strong organic performance
-
Entertainment1 week agoMartin Short: Facing tragedy with joy
-
Entertainment1 week agoTom Brady gets back at Kevin Hart during Netflix roast
-
Sports1 week agoJacob Fatu unleashes vicious assault on Roman Reigns after World Heavyweight Championship loss at WWE Backlash
-
Entertainment1 week agoMartha Stewart: How to make an omelet
-
Tech1 week agoCUDA Proves Nvidia Is a Software Company
